Actuate Therapeutics, Inc. (ACTU)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Actuate Therapeutics, Inc. (ACTU) trades at $1.45 with AI Score 26/100 (Grade F). Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer treatment. Market cap: $34.69M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for ACTU: ACTU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACTU against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACTU: 1/1 perspectives are bearish.
How is this calculated? →Actuate Therapeutics, Inc. (ACTU) Healthcare & Pipeline Overview
Actuate Therapeutics is a clinical-stage biopharmaceutical firm specializing in cancer therapies, with a focus on Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor. Targeting difficult-to-treat cancers like metastatic pancreatic ductal adenocarcinoma, Actuate operates within the competitive biotechnology sector, emphasizing innovative drug development.
What Is the Investment Thesis for ACTU?
Actuate Therapeutics presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The core value driver is the successful development and commercialization of Elraglusib, their lead drug candidate. Positive clinical trial results, particularly in metastatic pancreatic ductal adenocarcinoma, could significantly increase the company's valuation. The company's low beta of 0.12 suggests low volatility relative to the market. Upcoming clinical trial data releases for Elraglusib in various cancer types represent key catalysts. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for substantial additional funding to support ongoing research and development. Given its market cap of $34.69M, Actuate is a micro-cap company, making it susceptible to significant price swings based on news flow.
Based on FMP financials and quantitative analysis
ACTU Key Highlights
- Lead product candidate Elraglusib Injection targets metastatic pancreatic ductal adenocarcinoma, an area of high unmet medical need.
- Elraglusib is a novel glycogen synthase kinase-3 (GSK-3) inhibitor, representing a unique approach to cancer therapy.
- The company is also developing Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer, expanding its potential market.
- Actuate Therapeutics is a clinical-stage company, indicating that its products are still in the development and testing phase.
- The company's low beta of 0.12 suggests lower volatility compared to the broader market, but this may also reflect its early stage of development.
Who Are ACTU's Competitors?
ACTU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACTU's Key Strengths?
- Novel GSK-3 inhibitor mechanism of action.
- Focus on difficult-to-treat cancers with high unmet need.
- Proprietary Elraglusib Injection with patent protection.
- Experienced management team with expertise in drug development.
What Are ACTU's Weaknesses?
- Clinical-stage company with no approved products.
- Limited financial resources and reliance on external funding.
- Small size and limited infrastructure compared to larger competitors.
- High risk of clinical trial failure.
What Could Drive ACTU Stock Higher?
- Release of Phase 2 clinical trial data for Elraglusib in metastatic pancreatic ductal adenocarcinoma (expected in late 2026).
- Initiation of Phase 1/2 clinical trial for Elraglusib in combination with other therapies (expected in early 2027).
- Enrollment and progress in ongoing clinical trials for Elraglusib in Ewing sarcoma, metastatic melanoma, and colorectal cancer.
- Potential for orphan drug designation for Elraglusib in Ewing sarcoma.
What Are the Key Risks for ACTU?
- Financial-distress signal — its Altman Z-Score of -28.37 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays in Elraglusib development.
- Regulatory hurdles and potential rejection of drug applications by the FDA.
- Competition from established cancer therapies and new entrants in the biotechnology industry.
- Difficulty securing additional funding to support ongoing research and development activities.
- Intellectual property challenges and potential loss of patent protection for Elraglusib.
What Are the Growth Opportunities for ACTU?
- Elraglusib Development for Pancreatic Cancer: The primary growth opportunity lies in the successful development and commercialization of Elraglusib for metastatic pancreatic ductal adenocarcinoma. The pancreatic cancer therapeutics market is projected to reach $4 billion by 2028, driven by the high unmet need for effective treatments. Positive Phase 2 and Phase 3 trial results could lead to FDA approval and significant revenue generation for Actuate. The timeline for potential approval is estimated within the next 3-5 years, contingent on clinical trial outcomes.
- Expansion into Ewing Sarcoma Treatment: Actuate is also exploring Elraglusib's potential in treating Ewing sarcoma, a rare cancer primarily affecting children and young adults. The market for Ewing sarcoma treatments is smaller but has significant unmet needs, offering potential for orphan drug designation and accelerated regulatory pathways. The global Ewing sarcoma treatment market is projected to reach $300 million by 2027. Clinical trials are ongoing, with potential for initial results within the next 2 years.
- Application in Metastatic Melanoma: The development of Elraglusib for metastatic melanoma represents another growth avenue. Melanoma is a more common and well-studied cancer, but effective treatments for advanced stages remain a challenge. The global melanoma therapeutics market is projected to reach $11 billion by 2028. Actuate's approach could offer a novel treatment option, particularly for patients who have failed other therapies. Clinical trial data will be crucial in determining the viability of this indication within the next 2-3 years.
- Elraglusib for Colorectal Cancer Treatment: Actuate is investigating Elraglusib's efficacy in treating colorectal cancer, one of the most prevalent cancers worldwide. The colorectal cancer therapeutics market is substantial, projected to reach $19 billion by 2028. Success in this indication would significantly expand Elraglusib's market potential. Clinical trials are in early stages, with potential for preliminary data within the next 3 years.
- Strategic Partnerships and Licensing Agreements: Actuate can pursue growth through strategic partnerships with larger pharmaceutical companies. Licensing agreements for Elraglusib in specific territories or indications could provide upfront payments, milestone payments, and royalties, providing non-dilutive funding and expanding the drug's reach. This strategy could be implemented at any time, depending on clinical trial progress and market interest.
What Opportunities Does ACTU Have?
- Positive clinical trial results leading to regulatory approval.
- Expansion into additional cancer indications.
- Strategic partnerships with larger pharmaceutical companies.
- Orphan drug designation for rare cancers.
What Threats Does ACTU Face?
- Clinical trial failures or delays.
- Regulatory hurdles and rejection of drug applications.
- Competition from established cancer therapies and new entrants.
- Difficulty securing funding and maintaining financial stability.
What Are ACTU's Competitive Advantages?
- Patented Elraglusib Injection provides exclusivity.
- Novel GSK-3 inhibition mechanism offers a differentiated approach.
- Clinical trial data demonstrating efficacy and safety creates a barrier to entry.
- Orphan drug designation (if obtained) provides market exclusivity and regulatory advantages.
What Does ACTU Do?
Actuate Therapeutics, Inc., established in 2015 and based in Fort Worth, Texas, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of various cancers. Originally named Apotheca Therapeutics, Inc., the company rebranded in October 2015 to reflect its refined focus on cancer therapeutics. Actuate's primary focus is on Elraglusib Injection, a novel glycogen synthase kinase-3 (GSK-3) inhibitor. This drug is being developed to target metastatic pancreatic ductal adenocarcinoma, a particularly aggressive and challenging form of cancer to treat. Beyond pancreatic cancer, Actuate is also exploring the potential of Elraglusib in treating other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. As a clinical-stage company, Actuate is heavily involved in research and development, conducting clinical trials to evaluate the safety and efficacy of Elraglusib. The company's strategy revolves around identifying and developing targeted therapies that can improve outcomes for cancer patients, particularly those with limited treatment options. Actuate operates within the highly competitive biotechnology industry, where innovation and clinical success are critical for long-term growth and sustainability. The company's relatively small size allows for agility and focused execution, but also necessitates strategic partnerships and efficient use of capital to advance its clinical programs.
What Products and Services Does ACTU Offer?
- Develops Elraglusib Injection, a novel glycogen synthase kinase-3 (GSK-3) inhibitor.
- Targets metastatic pancreatic ductal adenocarcinoma with Elraglusib.
- Conducts clinical trials to evaluate the safety and efficacy of Elraglusib.
- Explores Elraglusib's potential in treating Ewing sarcoma.
- Investigates Elraglusib's application in metastatic melanoma.
- Researches Elraglusib's effectiveness in treating colorectal cancer.
- Focuses on developing therapies for the treatment of cancers.
How Does ACTU Make Money?
- Develops and patents novel cancer therapies.
- Conducts clinical trials to gain regulatory approval.
- Seeks to commercialize approved therapies directly or through partnerships.
- Generates revenue through drug sales and licensing agreements.
What Industry Does ACTU Operate In?
Actuate Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. The competitive landscape includes large pharmaceutical companies, established biotechnology firms, and numerous smaller companies all vying to develop and commercialize novel cancer treatments. Actuate's focus on GSK-3 inhibition represents a differentiated approach, but the company faces competition from other therapies targeting similar cancer types. The success of Actuate depends on its ability to navigate the complex regulatory environment, secure funding, and demonstrate clinical efficacy.
Who Are ACTU's Key Customers?
- Cancer patients suffering from metastatic pancreatic ductal adenocarcinoma.
- Patients with Ewing sarcoma, metastatic melanoma, and colorectal cancer.
- Hospitals and oncology clinics that administer cancer treatments.
- Pharmaceutical companies that may license or partner on Actuate's therapies.
Key Financial Metrics
Its free cash flow yield is -40.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -45.3%, the inverse of the P/E and a quick read on earnings relative to price.
Actuate Therapeutics, Inc. (ACTU) Valuation Context
Valued at $34.69M, ACTU is classified as a micro-cap stock. Relative to its peer group, ACTU's quantitative score of 26/100 is below the peer average of 85/100.
Company Profile
Actuate Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Fort Worth, US. The company is led by CEO Daniel Schmitt. ACTU has traded publicly since 2024.
F-Score 2/9Financial Health
Actuate Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.37 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Actuate Therapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.80.
ACTU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Actuate's recent insider buying suggests confidence in the company's direction, mirroring situations like when insiders loaded up on Amazon before key growth phases. Community sentiment indicates growing optimism around Actuate's novel approach to cancer treatment. The market seems to be warming up to biotech companies with innovative platforms, which could benefit Actuate. There's a buzz among investors who see Actuate as a potential disruptor in the oncology space, similar to early perceptions of companies pioneering gene editing.
Bear Case
- Some investors are wary of Actuate's relatively small market cap, drawing parallels to the volatility seen in other micro-cap biotechs. Concerns exist within the community regarding the lengthy drug development process and potential regulatory hurdles, reminiscent of the challenges faced by many biotech startups. There's skepticism about whether Actuate's approach will ultimately translate to clinical success, a common fear in the high-risk biotech sector. Negative chatter suggests that the company might face difficulties in securing additional funding if clinical trials don't yield positive results.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ACTU Latest News
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jun 9, 2026
ACTU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACTU.
Price Targets
Wall Street price target analysis for ACTU.
ACTU MoonshotScore
What does this score mean?
The MoonshotScore rates ACTU's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Daniel Schmitt
CEO
Daniel Schmitt serves as the CEO of Actuate Therapeutics, Inc. He has extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. His career spans various leadership roles in both large pharmaceutical companies and smaller biotechnology firms. He has a strong background in strategic planning, business development, and fundraising. He manages a team of 10 employees at Actuate Therapeutics.
Track Record: Under Daniel Schmitt's leadership, Actuate Therapeutics has advanced Elraglusib Injection through multiple clinical trials, targeting various cancer indications. He has overseen the company's fundraising efforts and strategic partnerships. Key milestones include initiating Phase 2 trials for pancreatic cancer and expanding the development program to include Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Actuate Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does Actuate Therapeutics Inc do?
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancers. Their lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 (GSK-3) inhibitor. This drug is currently in clinical development for the treatment of metastatic pancreatic ductal adenocarcinoma, a particularly aggressive form of cancer. The company is also exploring the potential of Elraglusib in treating other cancers, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Actuate's business model revolves around developing and commercializing targeted therapies that can improve outcomes for cancer patients.
What do analysts say about ACTU stock?
As a micro-cap, clinical-stage biopharmaceutical company, Actuate Therapeutics is not widely covered by analysts. Any potential analyst ratings or price targets should be viewed with caution due to the inherent risks and uncertainties associated with drug development. Key valuation metrics would likely focus on the potential market size for Elraglusib, the probability of clinical trial success, and the likelihood of regulatory approval. Growth considerations center on the successful execution of clinical trials and the ability to secure funding to support ongoing development efforts. It is important to note that investing in companies like Actuate involves a high degree of risk.
What are the main risks for ACTU?
Actuate Therapeutics faces several key risks inherent to its business model and industry. The primary risk is the potential failure of Elraglusib in clinical trials, which would significantly impact the company's value. Regulatory hurdles and potential rejection of drug applications by the FDA also pose a significant risk. Competition from established cancer therapies and new entrants in the biotechnology industry could limit Actuate's market share. Securing additional funding to support ongoing research and development activities is crucial, and any difficulty in raising capital could hinder the company's progress. Intellectual property challenges and potential loss of patent protection for Elraglusib also represent a risk to the company's long-term prospects.
What are the key factors to evaluate for ACTU?
Actuate Therapeutics, Inc. (ACTU) holds an AI score of 26/100 (low). Not financial advice.
How frequently does ACTU data refresh on this page?
ACTU prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ACTU's recent stock price performance?
Actuate Therapeutics, Inc. (ACTU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel GSK-3 inhibitor mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACTU overvalued or undervalued right now?
Valuing Actuate Therapeutics, Inc. (ACTU) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ACTU?
Before investing in Actuate Therapeutics, Inc. (ACTU), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment in clinical-stage biopharmaceutical companies is highly speculative and involves significant risk.